Mazindol controlled release - NLS Pharma

Drug Profile

Mazindol controlled release - NLS Pharma

Alternative Names: NLS 1001; NLS-1

Latest Information Update: 22 Jun 2017

Price : $50

At a glance

  • Originator NLS Pharma
  • Class Anorectics; Small molecules
  • Mechanism of Action Adrenergic uptake inhibitors; Central nervous system stimulants; Dopamine uptake inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Narcolepsy
  • New Molecular Entity No

Highest Development Phases

  • Phase II Attention-deficit hyperactivity disorder; Narcolepsy

Most Recent Events

  • 22 Jun 2017 Chemical structure information added
  • 31 May 2017 Adverse events and efficacy data from a phase II trial in Attention-deficit hyperactivity disorder released by NLS Pharma
  • 18 Apr 2017 NLS Pharma has patent protection for mazindol for the treatment of Attention-deficit hyperactivity disorder in the US, Europe and Japan
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top